David M. Berman
Oncology · 2002–2015
A researcher in the Science corpus: 6 papers; trusts 3 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 83 citations into it
- Molecular Biology — 69 citations into it; #14,913 of 17,773 by trust here, #4,843 by citations
- Genetics — 24 citations into it
Whom David M. Berman trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts David M. Berman overall
Papers from David M. Berman's perspective
Ordered by how strongly the researchers David M. Berman trusts endorse each paper. Same corpus, a different order for every researcher.
- The Hedgehog and Wnt signalling pathways in cancer
- Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine (Nature)
- Small molecule modulation of Smoothened activity (Proceedings of the National Academy of Sciences of the United States of America)
- Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. (Genes & Development)
- Stem cells, cancer, and cancer stem cells (Nature)
- Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade (Science)
- Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. (Development)
- WNT signalling molecules act in axis formation in the diploblastic metazoan Hydra (Nature)
- Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells (Nature)
- Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas (Nature)
Their papers
- A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing (2007) — 1,146 citations
- Tissue repair and stem cell renewal in carcinogenesis (2004) — 1,214 citations
- Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer (2003) — 1,118 citations
- Medulloblastoma Growth Inhibition by Hedgehog Pathway Blockade (2002) — 838 citations
- Evolving synergistic combinations of targeted immunotherapies to combat cancer (2015) — 621 citations
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. (2005) — 1,709 citations